An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
Led by Dr Dan Worthley, Associate Professor Susan Woods and Dr Josephine Wright from SAHMRI and the University of Adelaide, in partnership with Professor Jeff Hasty at the University of California San Diego (UCSD), the study was published today in the prestigious journal, Science.
The team engineered bacteria called Acinetobacter baylyi (A. baylyi), which is known for its ability to sample and integrate DNA from its environment. Researchers leveraged this natural competence to detect the mutated KRAS gene, an important driver of colorectal cancer.
A/Prof Woods says they dubbed this technology ‘CATCH’, which stands for, Cellular Assay of Targeted CRISPR-discriminated Horizontal gene transfer.
“CATCH has the potential to detect bowel cancer early with the aim of preventing more people from dying of this and other cancers,” she said.
“This study demonstrates how bacteria can be designed to detect specific DNA sequences to diagnose disease in hard-to-reach places.”
In preclinical testing, the team found that the sensor bacteria were 100% accurate in differentiating between models with and without colorectal cancer.
“We were thrilled to see transfer of DNA from the tumour to the sensor bacteria,” A/Prof Woods said.
“This shows that our biosensing system can be used to catch colorectal cancer DNA within a complex ecosystem.”
Dr Dan Worthley says potential applications of the technology extend beyond cancer.
“In the future we will detect and prevent many diseases, including bowel cancer, with cells, not drugs,” he said.
“We hope that this invention, of life detecting life, will be useful for clinicians, scientists and engineers to help the community wherever and whenever DNA detection is important.”.
While further studies are needed before progressing to clinical trials, researchers are confident this latest discovery represents a significant advance in the field of living diagnostics while setting the stage for the timely and accurate delivery of targeted treatments.
-
Next Generation Condom Contraception, Dr Simon Cook
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
-
Dr Lisa Melton
RESEARCH IN SANFILIPPO
@ SANFILIPPO CHILDREN’S FOUNDATION
SYDNEY, NEW SOUTH WALES, AUSTRALIA -
Inner ear organoids for the study of human hearing and balance
Dr Jackie Ogier is an auditory neuroscientist, with a research focus on the molecular biology of hair cells, the specialised sensory receptors in the ear that detect sound and balance. She is a postdoctoral research fellow in the laboratory of A/Prof Bryony Nayagam, supported by a prestigious Passe and Williams foundation fellowship.
Dr Ogier’s experience broadly spans the genetics of hearing loss, disease modelling, micro dissection, primary cell culture, stem cell culture, organoids, and proteomics. Overall, she aims to generate knowledge of hearing and vestibular sensory biology.
